Fragile promise of psychedelics in psychiatry
Cédric Lemarchand, Raphaël Chopin, M Paul, Alain Braillon, Lisa Cosgrove, Ioana A. Cristea, Eiko I. Fried, Erick H. Turner, Florian Naudet
BMJ November 19, 2024 Peer reviewed DOI: 10.1136/bmj-2024-080391 via OpenAlex
Summary
Cédric Lemarchand and colleagues emphasize significant weaknesses in the existing evidence regarding the efficacy and safety of hallucinogens. They raise concerns about the appropriateness of using expedited regulatory pathways for these substances, suggesting that more robust data is needed before such measures are implemented.
Study at a glance
| Key finding | There are notable weaknesses in the evidence on the efficacy and safety of hallucinogens. |
|---|
Abstract
Cédric Lemarchand and colleagues highlight weaknesses in the evidence on efficacy and safety of hallucinogens and question the use of expedited regulatory pathways